Future studies will therefore investigate the effects of DYRK1A modulation in the cortex using AAV-based gene delivery to determine its impact on cognitive function, AD pathology, and neuroinflammation in mouse models of AD as well as explore potential combinational therapeutic synergistic effects (e.g., DYRK1A gene therapy and Aβ/tau inhibitor) on AD pathology. The gene discussed is DYRK1A; the disease is Alzheimer disease.